Roche's glofitamab Phase 2 trial in untreated DLBCL posts results after primary completion
Roche's NCT04980222 study testing glofitamab added to R-CHOP in ctDNA high-risk lymphoma patients has posted results following primary completion in September 2024.
Roche's single update this week concerns a Phase 2 glofitamab combination trial in first-line lymphoma treatment.
- Roche (Hoffmann-La Roche) sponsors a Phase 2, single-arm study testing glofitamab in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone as a first-line treatment for individuals with circulating tumor DNA high-risk diffuse large B-cell lymphoma1. The trial is now listed as active, not recruiting, with enrollment of 46 participants1 and primary completion recorded as September 24, 2024; results were first posted August 18, 2026. The primary outcome is End of Treatment Complete Response Rate.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.